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ABSTRACT 
Aims: Endoglin is a transmembrane glycoprotein, that plays an important role in 
regulating endothelium. Proteolytic cleavage of membrane endoglin releases soluble endoglin 
(sEng), whose increased plasma levels have been detected in diseases related to the 
cardiovascular system. It was proposed that sEng might damage vascular endothelium, but 
detailed information about the potential mechanisms involved is not available. Thus, we 
hypothesized that sEng contributes to endothelial dysfunction, leading to a pro-inflammatory 
phenotype by a possible modulation of the TGF- and/or inflammatory pathways. 
Main methods: Human umbilical vein endothelial cells (HUVECs) and Human 
embryonic kidney cell line (HEK293T) were treated with different sEng concentration and 
time in order to reveal possible effect on biomarkers of inflammation and TGF- signaling. 
IL6 and NFκB reporter luciferase assays, quantitative real-time PCR analysis, Western blot 
analysis and immunofluorescence flow cytometry were used.  
Key findings: sEng treatment results in activation of NF-κB/IL-6 expression, increased 
expression of membrane endoglin and reduced expression of Id-1. On the other hand, no 
significant effects on other markers of endothelial dysfunction and inflammation, including 
eNOS, peNOS
 S1177
, VCAM-1, COX-1, COX-2 and ICAM-1 were detected.  
Significance: As a conclusion, sEng treatment resulted in an activation of NF-κB, IL-
6, suggesting activation of pro-inflammatory phenotype in endothelial cells. The precise 
mechanism of this activation and its consequence remains to be elucidated. A combined 
treatment of sEng with other cardiovascular risk factors will be necessary in order to reveal 
whether sEng is not only a biomarker of cardiovascular diseases, but also a protagonist of 
endothelial dysfunction. 
Key words: Soluble endoglin; Inflammation; NF-κB; IL-6; Endothelial cells 
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INTRODUCTION 
Membrane endoglin (CD105, Eng) is an accessory type III receptor for the 
transforming growth factor-β (TGF-β) superfamily of cytokines [1,2]. Membrane endoglin is 
a dimer composed of 95-kDa disulfide-linked subunits [3] and involves an extracellular 
domain of 561 amino acid residues, a single transmembrane domain of 25 amino acid 
residues, and a short intracellular domain of 47 amino acids that does not include a signal 
transduction domain. The cytosolic domain of endoglin can be targeted by serine and 
threonine kinases, including the TGF-β type I and II receptors [4]. Endoglin expression is 
restricted primarily to cells found in the vessel wall, including endothelial cells (ECs), 
monocyte/macrophages, as well as to various mesenchymal cells such as fibroblasts and 
vascular smooth muscle cells (SMCs) [5]. In addition, it was demonstrated to play an 
important role in endothelial physiology/dysfunction and potentially in atherosclerosis [6].  
The membrane bound form of endoglin can be cleaved at its juxtamembrane region by 
the matrix metalloproteinase 14 (MMP14), releasing a soluble form of endoglin (sEng) into 
the circulation [7]. Increased plasma levels of sEng have been detected in various pathological 
conditions related to the cardiovascular system [8], including atherosclerosis [6], type II 
diabetes mellitus [9] and preeclampsia, where sEng levels correlate with disease severity [10], 
suggesting it might be a useful biomarker of these diseases progression. Furthermore, several 
authors have postulated that sEng might induce damage to the vascular endothelium, a topic 
that we have reviewed recently [1].  
Membrane endoglin can bind TGF-β1 and TGF-β3 isoforms in association with TGF-
β receptors II and I (ALKs) and form a functional receptor complex [11]. Moreover, in vitro 
studies demonstrated that membrane endoglin affects TGF-β signaling by modulating the 
activity of Smad transcription factors [12,13]. Several studies have revealed an interplay 
between two signaling pathways involving membrane endoglin. Membrane endoglin/ALK-
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1/Smad1/5 signaling has been shown to stimulate endothelial cell migration, proliferation and 
tube formation resulting in increased angiogenesis [14]. On the contrary, activation of the 
membrane endoglin/ALK-5/Smad2 pathway inhibits the activity of endothelial cells, blocks 
angiogenesis by inhibition of EC proliferation, tube formation and migration, and keeps 
endothelium quiescent [15,16]. Indeed it was proposed that also soluble endoglin modulates 
TGF-β family members and their downstream signaling pathways, including TGFβRII/ALK-
1/Smad1/5/ld1 pathway [17] and/or TGFβRII/ALK-5/Smad2/3/PAI-1 route [11].  
Membrane endoglin is strongly related to the expression and activity of endothelial 
NO synthase (eNOS) [18], a key enzyme for the proper function of the vascular endothelium 
[19]. Indeed, altered expression of eNOS or eNOS phosphorylated on serine 1177 
(peNOS
S1177
) is involved in endothelial dysfunction and atherogenesis [20]. On the other 
hand, membrane endoglin was proposed to participate in inflammation by promoting 
leukocyte adhesion and transmigration [21]. Inflammation is a general key process in the 
development of endothelial dysfunction. Increased expression of cell adhesion molecules such 
as vascular cell adhesion molecule (VCAM-1), intercellular adhesion molecule (ICAM-1), 
monocyte chemoattractant protein-1 (MCP-1) [22], cyclooxygenase-1 (COX-1), or 
cyclooxygenase-2 COX-2 [23], represents a crucial step for the development of endothelial 
inflammation/dysfunction. The activated expression of the pro-inflammatory molecules 
VCAM-1 and ICAM-1 is the ultimate consequence of NF-κB-dependent signaling [24,25]. 
The nuclear factor NF-kappaB (NF-κB) is a transcription factor involved in many biological 
processes such as inflammation, cell growth, differentiation, immunity and apoptosis [26,27]. 
Moreover, TGF-β was shown to affect NF-κB expression and signaling [28,29]. NF-κB 
cooperates with many other signaling molecules, pathways and transcription factors, such as 
Signal transducer and activator of transcription 3 (STAT3) [26] and it is an important 
regulator for IL-6 gene, which has putative binding sites for NF-κB [30]. IL-6 is a 
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multifunctional cytokine that plays a central role in inflammation and immune response [31]. 
Circulating IL-6 is produced by activated inflammatory cells within the vessel wall. Thus, 
NF-κB/IL-6 signaling seems to be important to trigger vascular inflammation [24]. 
Although sEng has been proposed to participate in the development of endothelial 
dysfunction [1], detailed information about the potential mechanisms involved is not 
available. Thus, we hypothesized that sEng contributes to endothelial dysfunction, leading to 
a pro-inflammatory phenotype by a possible modulation of the TGF- signaling pathway. 
Therefore, we focused on the effects of sEng treatment on endothelial dysfunction markers, 
biomarkers of inflammation and TGF- signaling in cultured human endothelial cells. 
 
MATERIALS AND METHODS 
Cell culture 
Human umbilical vein endothelial cells (HUVECs) are primary cells isolated from 
pooled donors and purchased from Lonza (Basel, Switzerland). HUVECs were grown in 
EBM-2 medium containing 10% fetal bovine serum (FBS) (Sigma-Aldrich, Czech Republic) 
and supplemented with EGM-2 SingleQuots (Lonza, France) at 37°C and 5% CO2. In all 
experiments, HUVECs were cultured in 0.1% gelatin-coated (Sigma-Aldrich) Petri dishes. All 
experiments were performed with HUVECs at passages between 4 and 9. For starving 
conditions, HUVECs were incubated for 24 hours in the same medium, but containing 0% of 
FBS. Gelatin helps HUVECs to attach and grow as it acts as a extracellular matrix. In 
addition, culturing the cells in the presence of low serum concentration for a short period of 
time is a standard method to make cells more responsive to soluble factors. 
The human embryonic kidney cell line HEK293T was cultured in Dulbecco´s 
modified Eagle´s medium (DMEM) (Gibco, Massachusetts, USA) and supplemented with 
10% FBS (Gibco), 100U/mL penicillin and 100U/mL streptomycin (Gibco) at 37ºC and 5% 
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CO2. Recombinant human endoglin and TNFα were purchased from R&D Systems 
(Minnesota, USA). The sEng and TNFα stock solutions of 250 µg/mL and 10 µg/mL 
respectively were prepared in sterile PBS containing 0.1% bovine serum albumin (Biosera, 
France) and aliquots were stored at -20°C. All the treatments were done with medium 
containing 0-2% FBS and selected concentrations of sEng (40 ng/mL and 500 ng/mL). 
Concentrations of sEng used in the manuscript were selected within the range of the 
concentrations found in women with preeclampsia and in a mouse model of preeclampsia that 
over-expresses soluble human endoglin [32-34]. 2 hours treatment was used for the evaluation 
of phosphorylation of Smads and eNOS
S1177
. 16 hours treatment were used for the evaluation 
of changes of all genes and endoglin, VCAM-1, Id-1 and COX-2 expression on protein level. 
24 hours treatment was used for the evaluation of IL-6 protein levels in cultured medium, and 
for Luciferase reporter activity assays of IL-6 and NF-κB. 48 hours soluble endoglin 
treatment was used for the NF-κB expression. 
 
Luciferase reporter activity of different promoter constructions 
The IL6 reporter vector encodes the luciferase driven by the IL6 promoter. The NFκB 
reporter encodes the luciferase driven by a regulatory sequence containing consensus motifs 
for NFκB binding and therefore is responsive to NFκB activation. The plasmid pKBF-
Luc/NF-κB contains three repeats of the NF-κB consensus elements present in the H-2Kb 
gene upstream of the herpes simplex thymidine kinase gene [35]. The pGL3-IL-6-Luc 
reporter construct driven by a 651-bp promoter fragment of human IL-6 [36] was kindly 
provided by Dr. Manuel Fresno (Centro de Biología Molecular Severo Ochoa (CSIC-UAM), 
Cantoblanco, Madrid, Spain). Transient co-transfection of HEK293T cells was conducted 
using Lipofectamine 2000 (ThermoFisher Scientific, California, USA) adding 0.8 µg of the 
pKBF promoter luciferase vector or pGL3-IL6-Luc reporter vector plus 50 ng of pCMV-βgal 
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vector (Clontech, France) to normalize for transfection efficiency, according to the 
manufacturer´s instructions. For a positive control, cells were treated with 5 ng/mL TNF-α 
during 24 hours. As indicated, cells were treated with 40 ng/mL and 500 ng/mL of sEng. Cells 
were analyzed 48 hours after transfection and luciferase relative units were determined in a 
Glomax multidetection system (Promega, Wisconsin, USA). Fold induction was defined as 
the ratio of relative light units (RLU) produced in treated cells to the RLU produced in 
untreated cells.  
 
Quantitative real-time PCR 
For quantitative real-time PCR analysis (qRT-PCR), HUVECs were treated with  
40 ng/mL or 500 ng/mL of sEng for 16 hours. Gene expression of ENG, GAPDH,  
VCAM-1, ID1, SERPINE1, NOS3 (eNOS), ACVRL1 (ALK-1), TGFBR1, TGFBR2, PTGS1 
(COX-1), PTGS2 (COX-2), NF-κB, CCL2 (MCP-1) and STAT3 were examined on 7500 HT 
Fast Real-Time PCR System (ThermoFisher Scientific), as described previously [37]. Total 
RNA from HUVECs was isolated using TRI reagent (Sigma-Aldrich) or SpeedTools Total 
RNA Extraction Kit (Biotools, Florida, USA) according to the manufacturer’s protocol and 
directly converted into cDNA with a high capacity cDNA reverse transcription kit or iScript 
cDNA Synthesis Kit (ThermoFisher Scientific or BioRad, California, USA, respectively). 30 
ng of cDNA was loaded into the reaction and experiments were performed in duplicate. The 
amplifications were run using TaqMan® Fast Universal PCR Master Mix (ThermoFisher 
Scientific) and pre-designed TaqMan® Gene Expression Assay kits for the following genes: 
ENG (Hs00923996_m1), GAPDH (Hs02758991_g1), VCAM-1 (Hs01003372_m1), PTGS2 
(Hs00153133_m1), PTGS1 (Hs00377726_m1), ID1 (Hs03676575_s1), SERPINE1 
(Hs01126606_m1), NFΚB3 (Hs00153294_m1), NOS3 (Hs01574659_m1), CCL2 
(Hs00234140_m1), STAT3 (Hs01047580_m1), ACVRL1 (Hs00953798), TGFBR1 
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(Hs00610320), TGFBR2 (Hs00234253_m1) all provided by ThermoFisher Scientific. The 
time–temperature profile was as follows: 95°C for 3 min; 40 times: 95°C for 7 s, 60°C for  
25 s. The relative expression ratio was calculated as described previously [38]. The 
glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH) was used as a reference for 
normalizing data. Oligonucleotides for IL-6 gene were designed using Roche software for  
qRT-PCR, human IL-6 Fw 5`- GAAGGCAGCAGGCAACAC-3` and Rv  
5`-CAGGAGCCCAGCTATGAACT-3`. As an internal control, mRNA levels of 18S rRNA 
were measured using primers Fw 5´-CTCAACACGGGAAACCTCAC-3` and Rv  
5`-CGCTCCACCAACTAAGAACG-3`. In this case, amplicons were detected using a 
LightCycler 480 System II-384 (Roche Applied Biosciences, Switzerland). 
 
IL-6 ELISA  
HUVEC monolayers were treated with 40 ng/mL or 500 ng/mL of sEng in media 
without serum. Culture supernatants were collected after 24 hours and analyzed by ELISA. 
Concentration of human IL-6 in the cell culture media was determined according to the 
manufacturer protocol by Quantikine Human IL-6 assay (D6050; R&D Systems). The results 
of the immunoassay were measured in a Glomax Multidetection system (Promega) and 
normalized by the supernatant protein concentration (µg/mL) of each sample and by the 
control group levels (100%). 
 
Western blot analysis 
For detection of protein expression by Western blot analysis, cells were treated with 
40 ng/mL or 500 ng/mL of sEng for 2 hours (phospho Smads, peNOS) or 16 hours for the 
determination of endoglin and 48 hours for the determination of total NF-κB and 
phosphorylated NF-κB. Samples were homogenized in RIPA buffer (Sigma-Aldrich) 
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containing protease (SERVA Electrophoresis, Germany) and phosphatase inhibitors 
(ThermoFisher Scientific). Cell homogenates (20 µg of total protein) were separated as 
described previously [38]. Membranes were incubated overnight at 4ºC with primary 
antibodies including anti-human endoglin (sc-20632, Santa Cruz Biotechnology, California, 
USA) at 1:500 dilution, anti-human peNOS (sc-21871-R, Santa Cruz Biotechnology) at 1:200 
dilution, anti-human pSmad1/5 (9516, Cell Signaling, Massachusetts, USA) at 1:500 dilution, 
anti-human pSmad2/3 (8828, Cell Signaling) at 1:500 dilution, anti-human phospho - NF-κB 
(ab86299, Abcam, United Kingdom) at 1:2,000 dilution and anti-human NF-κB (ab16502, 
Abcam) at 1:500 dilution. Equal loading of total proteins was confirmed by immunodetection 
with anti-human GAPDH (G8795, Sigma-Aldrich) at 1:10,000 dilution. As secondary 
antibodies, horseradish peroxidase-linked goat anti-rabbit IgG-(Fab')2 (ab6112, Abcam) was 
used to detect all proteins except GAPDH, at different dilutions: 1:2,000 for anti-endoglin, 
anti-pSmad1/5, and anti-NF-κB; 1:1,000 for anti-peNOSS1177 and anti-pSmad2/3, and 1:4,000 
for anti-phospho-NF-κB. For anti-GAPDH detection, the secondary antibody horseradish 
peroxidase-conjugated goat anti-mouse IgG (Sigma-Aldrich) was used at 1:20,000 dilution. 
After washing with TBST buffer, membranes were developed using an enhanced 
chemiluminescent reagent (ThermoFisher Scientific). Quantification of immunoreactive 
bands on the exposed films was performed by image analysis software NIS (Laboratory 
Imaging, Czech Republic). 
 
Immunofluorescence flow cytometry 
For immunofluorescence flow cytometry, HUVECs were treated with 40 ng/mL or  
500 ng/mL of sEng for 16 hours in EBM-2 medium. HUVECs were rinsed with PBS, 
detached with trypsin and then incubated with fluorescein-conjugated mouse monoclonal 
antibody against human VCAM-1 (CD106; BBA22, R&D Systems) or anti-human endoglin 
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P4A4 mouse monoclonal antibody (Developmental Studies Hybridoma Bank, University of 
Iowa, USA) for 1 hour at 4°C. As a negative control for analysis, an irrelevant isotype control 
antibody IgG2A (IC002F, R&D Systems) was used. The determination of protein expression 
was performed using the cell staining protocol for flow cytometry on Cell Lab Quanta SC 
Flow Cytometer (Beckman Coulter, Inc., California, USA). A total number of 5,000 cells was 
analyzed per sample. Results are presented as relative expression index, calculated as a 
number of positive cells of the target sample multiplied by the mean fluorescence intensity, 
related to control samples as described previously [38]. 
 
Statistical analysis 
Results are expressed as mean ± SEM. All multiple comparison data were analyzed 
using ANOVA with Kruskal-Wallis test followed Dunn’s multiple comparisons test and direct 
group-group comparisons were carried out using the Mann-Whitney test. For the above-
mentioned statistical analysis, the GraphPad Prism 6.0 software (GraphPad Software, Inc., 
California, USA) was used. P values <0.05 were considered statistically significant.  
 
RESULTS 
Effect of sEng on endothelial dysfunction markers 
Expression analysis by qRT-PCR was used to test whether sEng treatment affects 
endothelial dysfunction and inflammation markers, such as VCAM-1, NOS3, NF-κB, STAT3, 
IL-6, CCL2, PTGS1, and PTGS2 (Fig. 1). Sixteen hours treatment with sEng (40 ng/mL and 
500 ng/mL) resulted in a significant increase of VCAM-1 mRNA expression (only at 500 
ng/mL) and NF-κB, IL-6, and PTGS2 in both tested sEng concentrations (Fig. 1). No 
significant effect of sEng treatment was detected for NOS3, STAT3, CCL2, and PTGS1 (Fig. 
1). 
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In addition, we analyzed significantly upregulated genes on protein level. At the 
protein level, VCAM-1 analysis using immunofluorescence flow cytometry showed no 
significant effect upon sEng treatment (Fig. 2). Similarly, protein expression levels of 
peNOS
S1177
 (endothelial NO synthase phosphorylated at serine 1177, showing increased 
activity of this enzyme) in total cell extracts showed no significant changes after 2 hours of 
treatment with 500 ng/mL of sEng under starving conditions, as determined by Western blot 
analysis (Fig. 2). In the same experiment, no significant changes of COX-2 were detected. 
 
Fig. 1. Gene expression of endothelial dysfunction markers. HUVECs were incubated with 
different concentrations of sEng (40 ng/mL and 500 ng/mL) for 16 hours. Total RNA was 
subjected to qRT-PCR using probes specific for genes related to endothelial dysfunction and 
inflammation. mRNA expression of VCAM-1 (a), NOS3 (b), NF-κB (c), STAT3 (d), IL-6 (e), 
CCL2 (f), PTGS1 (g), PTGS2 (h) are shown. GAPDH or 18S rRNA were used as 
housekeeping genes to normalize the values. Representative data of six independent 
experiments with n=3 per experiment are shown. Results are expressed as mean ± SEM. All 
multiple comparison data were analyzed using ANOVA with Kruskal-Wallis test followed 
Dunn's multiple comparisons test. *P <0.05, **P <0.01 and ***P <0.001, ns >0.05 versus 
control samples.  
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Fig. 2. sEng treatment effects on VCAM-1, COX-2 and peNOS
S1177 
expression. For 
immunofluorescence flow cytometry quantification of VCAM-1 (a), HUVECs were treated 
with 40 ng/mL or 500 ng/mL of sEng for 16 hours in EBM-2 medium. Results are presented 
as relative expression index. For Western blot analysis of peNOS
S1177
, HUVECs were treated 
for 2 hours under starving conditions (b). For Western blot analysis of COX-2, HUVECs were 
treated for 16 hours (c). The top panel shows the densitometric analysis (control = 100%), 
whereas the bottom panel includes a representative immunoblot. Equal loading of samples 
was confirmed by immunodetection of GADPH. Representative data of three independent 
experiments with n=3 per experiment are shown. Results are expressed as mean ± SEM. All 
multiple comparison data (VCAM-1, COX-2) were analyzed using ANOVA with Kruskal-
Wallis test followed Dunn’s multiple comparisons test. Mann-Whitney test we used for the 
analysis of peNOS. ns >0.05 versus control samples. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
14 
 
 
 
Effect of sEng on components of TGF-β signaling  
To assess, whether sEng had any effect on selected members of TGF-β signaling 
pathway, we analyzed mRNA expression of ACVRL1, TGFBR1, TGFBR2, SERPINE1 and 
ID1 (Fig. 3). 16 hours treatment with sEng (40 ng/mL and 500 ng/mL) resulted in a 
significant increase of ACVRL1 (ALK-1) and ID1 (only at 500 ng/mL) mRNA expression 
(Fig. 3). No significant changes in mRNA expression of TGFBR1, TGFBR2, SERPINE1 were 
observed.  
Potential activation of TGF-β signaling was assessed by Western blot analysis of 
pSmad2/3 and pSmad1/5 protein expression (Fig. 4). The results showed a significant 
increase of pSmad2/3 protein expression after 2 hours of treatment with 500 ng/mL sEng (Fig. 
4), but no significant change in the protein expression of pSmad1/5 was observed when 
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compared to control (Fig. 4). In addition, we aimed to evaluate protein levels of Id-1, whose 
gene expression was increased upon treatment with sEng (500 ng/mL) for 16h (Fig. 3). 
Surprisingly Id-1 expression was significantly lower after 500 ng/mL of sEng treatment when 
compared to control (Fig. 4). 
 
Fig. 3. Gene expression of ACVRL1 (a), TGFBR1 (b), TGFBR2 (c), SERPINE1 (d) and ID1 
(e). HUVECs were incubated with different concentrations of sEng (40 ng/mL and 500 
ng/mL) for 16 hours. Representative data of six independent experiments with n=3 per 
experiment are shown. Results are expressed as mean ± SEM. All multiple comparison data 
were analyzed using ANOVA with Kruskal-Wallis test followed Dunn’s multiple 
comparisons test. *P <0.05 and ***P <0.001, ns >0.05 versus control samples. 
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Fig. 4. Protein expression levels of pSmad2/3 (a), pSmad1/5 (b) analyzed by Western blot 
after 2 hours of treatment with 40 ng/mL or 500 ng/mL sEng under the starving conditions. 
Id-1 expression (c) analyzed by Western blot after 16 hours of treatment with 40 ng/mL or 
500 ng/mL sEng. Presented data show one representative of three independent experiments 
with n=3 per experiment for Western blot analysis. A densitometric analysis (control = 100%) 
has been done and equal loading of samples was confirmed by immunodetection of GADPH. 
Results are expressed as mean ± SEM. All multiple comparison data (Id-1) were analyzed 
using ANOVA with Kruskal-Wallis test followed Dunn’s multiple comparisons test. Mann-
Whitney test we used for the analysis of pSmad2/3 and pSmad1/5. *P <0.05, ns >0.05 versus 
control samples.  
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sEng treatment activates IL-6 promoter/gene reporter and IL-6 protein levels.  
Since significant differences in mRNA expression of IL-6 were detected, we wanted to 
test if sEng is able to stimulate the transcriptional activity of IL-6 (Fig. 5). The IL6 reporter 
vector encodes the luciferase driven by the IL6 promoter. Transient transfection experiments 
were performed in HEK293T cells with luciferase-IL-6-promoter (pGL3-IL-6-Luc). There is 
a clear marked activation of the IL-6 promoter vector due to sEng treatment (sEng: 40 ng/mL 
and 500 ng/mL for 24 hours). These results suggest that sEng is able to stimulate the 
transcriptional activity of IL-6 (Fig. 5). In addition, we confirmed a significant increase of IL-
6 protein levels in cultured media after 24 hours incubation with 40 ng/mL and 500 ng/mL of 
sEng in HUVECs. 
 
Fig. 5. IL-6 luciferase reporter expression in HEK293T cells transfected with pGL3-luc-IL-6 
vector. sEng effects on the activity of the IL-6-pGL3-luciferase promoter after 24h of 
treatment with sEng 40 ng/mL and 500 ng/mL (a). Results are normalized between empty-luc 
promoter vector pGL3 and expressed as a fold induction with respect to the basal activity of 
the IL-6-pGL3-luciferase promoter vector activity without treatment. Transfection efficiency 
was corrected by relating luciferase to β-galactosidase activity. This is one representative 
experiment of three independent ones. In the same experiment, TNFα was used as a positive 
control. HUVECs were treated with 40 ng/mL or 500 ng/mL sEng for 24 hours and protein 
levels of IL6 were measured by ELISA (b). IL6 protein levels were normalized for protein 
concentration and compared to those of untreated cells that were given an arbitrary value of 1. 
Representative data of three independent experiments with n=3 per experiment are shown. 
Results are expressed as mean ± SEM. All multiple comparison data were analyzed using 
ANOVA with Kruskal-Wallis test followed Dunn’s multiple comparisons test. *P <0.05 and 
**P <0.01, versus control samples.  
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sEng treatment activates NF-κB signaling and expression 
HEK293T cells and HUVECs were used to evaluate whether sEng affects the pro-
inflammatory activity, expression and phosphorylation of NF-κB. In order to evaluate sEng 
effects on transcriptional activity of NF-κB, HEK293 cells were transfected with pGL2-KBF-
luciferase reporter vector and incubated for 24 hours with increasing concentrations of sEng: 
40 ng/mL, and 500 ng/mL. The NF-κB reporter encodes the luciferase driven by a regulatory 
sequence containing consensus motifs for NF-κB binding and therefore is responsive to NF-
κB activation. Figure 6 shows an increment of pGL2-KBF-luc vector when compared to the 
basal levels of pGL2-KBF-Luciferase vector without treatment. To elucidate whether sEng 
affects NF-κB expression and phosphorylation status, a Western blot analysis was performed 
and phospho/total NF-κB ratio of intensities was determined. The results showed increased 
phosphorylation of NF-κB in HUVECs treated for 48 hours with 500 ng/mL of sEng (Fig. 6). 
 
Fig. 6. NF-κB expression and activity in HEK293 cells and HUVECs. HEK293T cells were 
transfected with pGL2-KBF-luciferase reporter vector and incubated for 24 hours with  
40 ng/mL, 100 ng/mL or 500 ng/mL of sEng (a). Results are represented as fold-induction 
values with respect to the activity of the untreated sample. This is one representative 
experiment of three independent ones. Protein expression of total and phospho-NF-κB (b). 
HUVECs were incubated in the absence or presence of 500 ng/mL of sEng for 48 hours. Total 
protein extracts were subjected to Western blot analysis using specific antibody to total and 
phospho-NF-κB. Results shown are representative of three independent experiments with n=3 
per experiment. The top panel represents the densitometric analysis (control=100%). The 
bottom panel includes a representative immunoblot. Results are expressed as mean ± SEM. 
All multiple comparison data were analyzed using ANOVA with Kruskal-Wallis test followed 
Dunn’s multiple comparisons test. Mann-Whitney test was used for the statistical analysis of 
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phospho/total NF-κB ratio of intensities by Western blot. *P <0.05, **P <0.01 and ns >0.05 
versus control samples. 
 
 
sEng treatment increases membrane endoglin expression in HUVECs 
To assess whether sEng can cause changes in mRNA and protein expression level of 
membrane endoglin, qRT-PCR and Western blot analyses were performed. Total RNA was 
subjected to qRT-PCR using probes specific for human endoglin. A significant upregulation 
of mRNA of endoglin is observed at the highest concentration of sEng (Fig. 7). In addition, 
Flow cytometry and Western blot analysis confirmed significant increase of the protein level 
after the treatment with 500 ng/mL of sEng (Fig. 7).  
 
Fig. 7. Endoglin expression levels after sEng treatment. Expression levels of human 
endoglin mRNA after 16 hours of treatment with 40 ng/mL and 500 ng/mL of sEng, as 
determined by qRT-PCR analysis (a). Protein expression levels of membrane endoglin after  
16 hours of treatment with 500 ng/mL of sEng (b). Protein expression levels of membrane 
endoglin after 16 hours of treatment with 40 ng/mL and 500 ng/mL of sEng, as determined by 
flow cytometry (c). Total protein extracts were subjected to Western blot analysis using 
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specific antibody to endoglin. The top panel shows the densitometric analysis (control = 
100%), whereas the bottom panel includes a representative immunoblot. Equal loading of 
samples was confirmed by immunodetection of GADPH. Flow cytometry results are 
presented as relative expression index. Representative data of three independent experiments 
with n=3 per experiment are shown. Results are expressed as mean ± SEM. All multiple 
comparison data were analyzed using ANOVA with Kruskal-Wallis test followed Dunn’s 
multiple comparisons test. Mann-Whitney test was used for the statistical analysis of endoglin 
expression by Western blot analysis. *P <0.05, **P <0.01 and ***P <0.001, ns >0.05 versus 
control samples.  
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DISCUSSION 
The results of this study show that sEng treatment results in activation of NF-κB/IL-6 
expression suggesting that sEng treatment is responsible for the partial development of  
pro-inflammatory phenotype in HUVECs.  
Increased levels of sEng are released from membrane bound endoglin into the circulation 
in different settings of cardiovascular pathophysiology, including hypercholesterolemia [1], 
hypertension [34], inflammation [21], atherosclerosis [39], endothelial injury [40], type II 
diabetes mellitus [9] and preeclampsia [17]. In addition to being a potential biomarker of 
these pathologies, the interaction of sEng with various members of TGF- resulting in 
manifestation of endothelium inflammation/alteration/dysfunction has been postulated 
[32,41,42]. Therefore, in this study, we hypothesized that high levels of sEng may contribute 
to inflammation/endothelial dysfunction of cultured human endothelial cells. 
A previous report has shown that sEng interacts with TGF-/Smad2/3 signaling pathway, 
leading to the inhibition of eNOS-dependent vasodilatation in isolated rat renal microvessels 
and mesenteric vessels [41]. In addition, adenovirus-driven expression of sEng resulted in 
neutralization of TGF- and VEGF effects with a subsequent increase in expression of P-
selectin and leukocyte rolling to endothelium, elevated levels of soluble E-selectin, soluble 
VCAM-1 and impaired vasodilatation [42]. sEng can scavenge BMP-9 and block BMP-9-
mediated Smad1/5/8 phosphorylation [17]. These background data prompted us to evaluate 
whether markers of endothelial inflammation/dysfunction were affected by sEng treatment at 
40 ng/mL and 500 ng/mL concentration. The dose 40 ng/mL is closely related to levels of 
sEng measured in patient with preeclampsia [43], whereas 500 ng/mL dose was used as a 
proof of concept of our hypothesis and is related to our previous in vivo experiments [32,33].  
.  
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Endothelial dysfunction is primarily related to the functional changes involving NO 
production and alteration of eNOS-dependent vasodilatation [44]. In addition, increased 
expression of cell adhesion molecules and other pro-inflammatory molecules, including MCP-
1, COX1, and COX2 was proposed to be involved in the manifestation of endothelial 
dysfunction and inflammation, which is a crucial step in the development of many 
cardiovascular diseases, such as atherosclerosis or hypertension [22,23,45]. Even though the 
above-mentioned biomarkers were not significantly affected by sEng on protein levels, we 
found that sEng treatment activates and increases gene expression and phosphorylation status 
of NF-κB (reflecting increased protein activity), which is a key inflammatory transcriptional 
factor. Moreover, NF-κB was demonstrated to activate the expression of many pro-
inflammatory molecules, including IL-6 [30]. Accordingly, in our study sEng treatment 
activated IL-6 expression. NF-κB and IL-6 were demonstrated to be related to the 
development of endothelial dysfunction and acute inflammation [46]. However, the fact that 
other NF-κB-regulated pro-inflammatory proteins were not affected by sEng suggests that 
sEng treatment by itself does not induce a complete inflammatory status in endothelial cells in 
our experimental design.  
Surprisingly, sEng treatment also resulted in an increased expression of membrane bound 
endoglin. Possible explanation of this increase might be related to the fact that the effect of 
soluble endoglin is related to the increase of Smad2/Smad3 phosphorylation, which is a 
downstream target of the TGF-beta signaling pathway. Supporting this interpretation is the 
fact that it has been shown that TGF-beta markedly enhances the expression of cell surface 
endoglin [47]. Membrane bound endoglin was suggested to potentiate eNOS activity, stability 
and expression via Smad2 signaling, which is important for the maintenance of physiological 
properties of endothelium in vivo [13]. On the other hand, membrane bound endoglin was 
proposed to be involved in transmigration of leukocytes during inflammatory reaction [21]. 
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Therefore, it is tempting to speculate that increased expression of endoglin, together with 
activation of NF-κB/IL-6 signaling, could be, at least partially, related to induced 
inflammation after sEng treatment in endothelial cells [48]. 
Because endoglin is a component of the TGF- receptor complex, we analyzed the 
expression levels of some members of the TGF- signaling pathway in order to evaluate a 
possible impact of increased endoglin expression. Previous studies demonstrated that endoglin 
modulates the TGFRII/ALK-1/Smad1/5/ld1 and TGFRII/ALK-5/Smad2/3/PAI-1 pathways 
[2]. However, in our study, expression levels of members of these signaling cascades were not 
affected by sEng, except for increased pSmad2/3 and decreased Id-1 expression. Intriguingly, 
Smad2/3 phosphorylation was induced by sEng without affecting the expression of the 
downstream target PAI-1, suggesting that this pathway is not fully activated after sEng 
treatment. Moreover, we found no changes of eNOS (Ser
1177
) phosphorylation in HUVECs as 
well, suggesting that endoglin/eNOS pathway is not activated as well. Id-1 is a transcription 
factor participating on TGF- signaling, however its precise role in inflammation is unknown. 
Protein levels of Id1 were reduced upon 500 ng/mL sEng treatment, although under the same 
conditions Id-1 transcripts were increased. The reasons for this discrepancy are unclear, but 
the existence of additional regulatory mechanisms such as post-transcriptional and post-
translational modifications may probably account for these differences. Of note, protein 
expression is expected to be more relevant than transcript levels with respect to the function 
of this transcription factor. We propose that reduced Id1 protein expression might be related 
to the fact that soluble endoglin has been postulated to antagonize the function of membrane 
endoglin [10,16]. Because membrane endoglin contributes together with ALK1/Smad1,5,8 to 
a signaling pathway that leads to an upregulation of Id1, then it would be expected that 
soluble endoglin downregulates Id1. This would be compatible with the increased 
phosphorylation of Smad 2,3 because ALK5 signaling is favored when ALK1/endoglin 
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signaling is inhibited. However, clear impact of reduced Id-1 expression on NF-κB and IL-6 
expression remains to be elucidated. In general, the precise consequences of increased 
endoglin expression after sEng treatment will be addressed in our prospective studies.  
Since sEng treatment only induces a partial inflammatory reaction in endothelial cells, we 
speculate that this could be related to the fact that some additional stimuli are needed. 
Although sEng is responsible for an increased arterial pressure in mice [34], the presence of 
high levels of sEng did not induce signs of endothelial dysfunction in mouse aorta [33]. 
However, it is of interest to mention that high levels of sEng will always be present in the 
circulation together with other possible risk factors of cardiovascular disease, including 
hypercholesterolemia or hyperglycemia. Indeed, we demonstrated very recently that a 
combination of a mild hypercholesterolemia and high levels of soluble endoglin increases 
markers of endothelial inflammation, including F-κB, in mouse aorta [32]. Thus, we 
propose that sEng may act more substantially in collaboration with other potential 
cardiovascular risk factors (oxLDL, glucose, or other circulating cells e.g. leukocytes or mural 
cells). Further studies on the complex impact of sEng in endothelial cells are currently being 
addressed in our laboratory. 
 
CONCLUSION 
 We report here for the first time that sEng treatment of endothelial cells results in an 
activation of the pro-inflammatory biomarkers NF-κB and IL-6, suggesting a potential 
contribution to the pro-inflammatory phenotype in endothelium. The precise mechanism of 
this activation and its consequence remains to be elucidated. Future studies on the combined 
action of sEng with other cardiovascular risk factors may help to better understand the role of 
sEng not only as a biomarker of cardiovascular diseases, but also as a contributor to 
endothelial dysfunction. 
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